Survodutide vs Setmelanotide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: BI 456906
Survodutide is an injectable dual agonist that hits both the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. It is being tested for obesity and for fatty liver disease (MASH), and it carries an FDA Breakthrough Therapy designation for MASH. It is still investigational and not approved for any use as of mid-2026.
Also: Imcivree, RM-493
Setmelanotide (brand name Imcivree) is a melanocortin-4 receptor (MC4R) agonist peptide and a genuine FDA-approved obesity drug, first cleared in 2020. It is not a general weight-loss shot like the GLP-1 drugs: it is a targeted therapy for rare genetic forms of severe obesity where a specific brain hunger circuit is broken. It is given as a once-daily subcutaneous injection and has since been approved for additional conditions including Bardet-Biedl syndrome and acquired hypothalamic obesity.
Key Comparison Insights
- Setmelanotide is FDA approved, while Survodutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Setmelanotide has stronger research evidence (FDA Approved) compared to Survodutide (Human Trials).
Detailed Comparison
| Attribute | Survodutide | Setmelanotide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The drug works on two fronts at once. The GLP-1 receptor arm dampens appetite, slows how fast the stomach empties, and improves blood sugar handling, the same lever that semaglutide pulls. The glucagon receptor arm is the twist: glucagon signaling raises energy expenditure and pushes the liver to burn fat rather than store it. The idea, still being proven out in trials, is that adding controlled glucagon activity to GLP-1 action burns more energy and clears liver fat faster than a GLP-1 drug alone, which is why survodutide is aimed squarely at fatty liver disease. | Deep in the hypothalamus there is a pathway that tells your brain you are full and that ramps up energy use. It runs through signals like leptin and POMC down to the MC4R receptor. In people with certain rare gene defects, such as POMC, PCSK1, or LEPR deficiency, that pathway is short-circuited upstream of MC4R, so the brain never gets the fullness signal and hunger is relentless. Setmelanotide bypasses the broken upstream step by binding and switching on MC4R directly, restoring the satiety and energy-expenditure signal. That is why it works specifically in these genetic and syndromic forms of obesity and would not be expected to fix common obesity the same way. |
| Common Dosing | Limited community data available See research protocols | 2-3 mg daily Once daily |
| Administration | Subcutaneous injection weekly | Subcutaneous injection daily |
| Typical Duration | Long-term use expected | Long-term / chronic use |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the more advanced incretin dual agonists, and the human data are real, not hypothetical. In a Phase 2 MASH trial published in the New England Journal of Medicine in 2024 (Sanyal et al.), 293 biopsy-confirmed patients got weekly survodutide or placebo for 48 weeks, and MASH improved without worsening fibrosis in 47% of the 2.4 mg group and 62% of the 4.8 mg group, versus 14% on placebo. A separate Phase 2 obesity study showed weight loss up to roughly 18.7% at 46 weeks in completers. In April 2026, Boehringer Ingelheim and Zealand Pharma reported that the Phase 3 SYNCHRONIZE-1 obesity trial hit its mark with about 16.6% average weight loss. Large Phase 3 MASH trials (LIVERAGE and LIVERAGE-Cirrhosis) are ongoing. The catch worth knowing: nausea, vomiting, and other GI side effects are common, as with the whole incretin class, and final approval is not expected before 2027. | The human evidence is strong but deliberately narrow, matching the rare diseases it treats. The pivotal single-arm, open-label phase 3 trials in POMC and LEPR deficiency, published in The Lancet Diabetes and Endocrinology in 2020, reported that 80 percent of POMC patients and 45 percent of LEPR patients achieved at least 10 percent weight loss at about one year, alongside large drops in hunger scores. A separate randomized, placebo-controlled phase 3 trial supported approval in Bardet-Biedl syndrome, and a 2024 open-label trial (VENTURE) extended evidence to children as young as two. The trials were small because these conditions are extremely rare, so the data are best read as convincing within those specific genetic populations rather than as evidence for obesity broadly. The common side effects are consistent and manageable: skin hyperpigmentation, injection-site reactions, nausea, and headache, with no serious treatment-related events reported in the core trials. This is a legitimate approved drug for defined genetic indications, not an off-label general weight-loss peptide. |
Frequently Asked Questions: Survodutide vs Setmelanotide
What is the difference between Survodutide and Setmelanotide?
Survodutide is a weight loss peptide that survodutide is an injectable dual agonist that hits both the glp-1 and glucagon receptors, developed by boehringer ingelheim and zealand pharma. it is being tested for obesity and for fatty liver disease (mash), and it carries an fda breakthrough therapy designation for mash. it is still investigational and not approved for any use as of mid-2026. Setmelanotide is a weight loss peptide that setmelanotide (brand name imcivree) is a melanocortin-4 receptor (mc4r) agonist peptide and a genuine fda-approved obesity drug, first cleared in 2020. it is not a general weight-loss shot like the glp-1 drugs: it is a targeted therapy for rare genetic forms of severe obesity where a specific brain hunger circuit is broken. it is given as a once-daily subcutaneous injection and has since been approved for additional conditions including bardet-biedl syndrome and acquired hypothalamic obesity. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Survodutide or Setmelanotide?
Neither is universally "better" - the choice depends on your specific goals. Survodutide is typically used for weight loss purposes, while Setmelanotide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Survodutide and Setmelanotide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Survodutide and Setmelanotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.